Terumo Corporation (TYO:4543)
Japan
· Delayed Price · Currency is JPY 2,369.00
-54.00 (-2.23%)
At close: Dec 5, 2025
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2012 - 2020 |
| Americas Revenue | 412.12B | 395.65B |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue | 226.53B | 218.29B |
Log In |
Log In |
Log In | Upgrade
|
| China Revenue | 85.52B | 84.97B |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Others Revenue | 118.09B | 120.05B |
Log In |
Log In |
Log In | Upgrade
|
| Japan Revenue | 220.16B | 217.21B |
Log In |
Log In |
Log In | Upgrade
|
Revenue
Fiscal year is April - March.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2012 - 2020 |
| Cardiac and Vascular Company Revenue | 640.15B | 624.36B |
Log In |
Log In |
Log In | Upgrade
|
| Medical Care Solutions Company Revenue | 212.60B | 211.24B |
Log In |
Log In |
Log In | Upgrade
|
| Blood and Cell Technologies Company Revenue | 209.35B | 200.28B |
Log In |
Log In |
Log In | Upgrade
|
| Adjustments from Revenue | 329.00M | 298.00M |
Log In |
Log In |
Log In | Upgrade
|
Adjusted EBIT
Fiscal year is April - March.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2012 - 2020 |
| Cardiac and Vascular Company Adjusted Operating Profit | 164.82B | 154.68B |
Log In |
Log In |
Log In | Upgrade
|
| Medical Care Solutions Company Adjusted Operating Profit | 23.78B | 22.99B |
Log In |
Log In |
Log In | Upgrade
|
| Blood and Cell Technologies Company Adjusted Operating Profit | 28.91B | 26.48B |
Log In |
Log In |
Log In | Upgrade
|
| Adjustments from Adjusted Operating Profit | -3.65B | -712.00M |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2012 - 2020 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2012 - 2020 |
| Cardiac and Vascular Company Production Result | 620.90B |
Log In |
Log In |
Log In | Upgrade
|
| Medical Care Solutions Company Production Result | 197.08B |
Log In |
Log In |
Log In | Upgrade
|
| Blood and Cell Technologies Company Production Result | 205.67B |
Log In |
Log In |
Log In | Upgrade
|
| Total Production Result | 1,023.65B |
Log In |
Log In |
Log In | Upgrade
|